文献速递传染病防控与疫情报告免疫规划

辉瑞-BioNTech新冠疫苗在两家养老院疫情中的有效性

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-03-19

美国康涅狄格州两家专业护理机构在首剂接种后发生新冠暴发,电子病历回顾显示部分接种对SARS-CoV-2感染的有效性为63%(95%CI=33%-79%)。结果提示应推荐完成两剂全程接种以优化该人群疫苗效果。

要点

  • 专业护理机构居民是新冠高 morbidity 和死亡率人群,但未纳入疫苗临床试验。
  • 部分接种(首剂后>14天至第二剂后7天)对SARS-CoV-2感染有效性63%(95%CI=33%-79%)。
  • 建议专业护理机构居民和工作人员完成两剂全程接种。

核心结论

  • 部分接种辉瑞-BioNTech新冠疫苗对专业护理机构居民SARS-CoV-2感染的有效性为63%(95%CI=33%-79%)。
  • 为优化该人群疫苗影响,应推荐高覆盖率的完整两剂系列接种。

研究设计与样本

  • 基于康涅狄格州两家发生新冠暴发的专业护理机构的电子病历回顾。

主要发现

  • 部分接种定义为第一剂后>14天至第二剂后7天,对SARS-CoV-2感染(无论症状)的估计有效性为63%(95%CI=33%-79%)。
  • 该有效性估计与辉瑞-BioNTech新冠疫苗单剂在非聚集环境中各年龄组成人的估计有效性相似。

关键数值与推荐

  • 部分接种:第一剂后>14天至第二剂后7天。
  • 部分接种对SARS-CoV-2感染有效性:63%(95%CI=33%-79%)。

临床怎么用

  • 应推荐专业护理机构居民和工作人员完成完整的两剂新冠疫苗接种系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Residents of long-term care facilities (LTCFs), particularly those in skilled nursing facilities (SNFs), have experienced disproportionately high levels of COVID-19-associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1,2). However, this group was not included in COVID-19 vaccine clinical trials, and limited postauthorization vaccine effectiveness (VE) data are available for this critical population (3). It is not known how well COVID-19 vaccines protect SNF residents, who typically are more medically frail, are older, and have more underlying medical conditions than the general population (1). In addition, immunogenicity of the Pfizer-BioNTech vaccine was found to be lower in adults aged 65-85 years than in younger adults (4). Through the CDC Pharmacy Partnership for Long-Term Care Program, SNF residents and staff members in Connecticut began receiving the Pfizer-BioNTech COVID-19 vaccine on December 18, 2020 (5). Administration of the vaccine was conducted during several on-site pharmacy clinics. In late January 2021, the Connecticut Department of Public Health (CT DPH) identified two SNFs experiencing COVID-19 outbreaks among residents and staff members that occurred after each facility's first vaccination clinic. CT DPH, in partnership with CDC, performed electronic chart review in these facilities to obtain information on resident vaccination status and infection with SARS-CoV-2, the virus that causes COVID-19. Partial vaccination, defined as the period from >14 days after the first dose through 7 days after the second dose, had an estimated effectiveness of 63% (95% confidence interval [CI] = 33%-79%) against SARS-CoV-2 infection (regardless of symptoms) among residents within these SNFs. This is similar to estimated effectiveness for a single dose of the Pfizer-BioNTech COVID-19 vaccine in adults across a range of age groups in noncongregate settings (6) and suggests that to optimize vaccine impact among this population, high coverage with the complete 2-dose series should be recommended for SNF residents and staff members.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Britton A, Jacobs Slifka KM, Edens C, et al. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33735160. doi:10.15585/mmwr.mm7011e3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。